1xbet 로그인 Pharmaceutical Co., Ltd.

Tokyo, Japan, February 25, 2013 - Otsuka Pharmaceutical Co., Ltd. (Otsuka) was awarded 1xbet 로그인 60th Annual Okochi Memorial Grand Technology Prize from 1xbet 로그인 Okochi Memorial Foundation, for 1xbet 로그인 development of aripiprazole, an antipsychotic medication. 1xbet 로그인 award ceremony will take place at 1xbet 로그인 Industrial Club of Japan on March 26, 2014.

1xbet 로그인 Okochi Memorial Prizes, with an esteemed reputation and history, are awarded to honor individuals and business entities making remarkable contributions in 1xbet 로그인 areas of industrial engineering and manufacturing techniques. 1xbet 로그인 awards were established in memory of Dr. Masatoshi Okochi for his distinguished services as former President of 1xbet 로그인 Institute of Physical and Chemical Research (widely known as RIKEN). 1xbet 로그인 Okochi Memorial Grand Technology Prize, which is 1xbet 로그인 superlative among 1xbet 로그인 Okochi prizes, is awarded annually to individuals singly or in small groups who contribute to academic and industrial advancement through original research on manufacturing and engineering techniques.

Otsuka was granted 1xbet 로그인 Okochi Memorial Grand Technology Prize for developing aripiprazole (marketed as ABILIFY®) as 1xbet 로그인 first-and-still-sole-third-generation antipsychotic.ABILIFY has a unique mechanism of action called dopamine D2 receptor partial agonism which improves both 1xbet 로그인 positive and negative symptoms of schizophrenia. Cutting-edge manufacturing and quality control processes for aripiprazole, as well as achievement and maintenance of a stable supply of active ingredients for large-scale production were also attributed factors for receipt of 1xbet 로그인 prize.

Otsuka Recipients of 1xbet 로그인 Okochi Memorial Grand Technology Prize

Yasuo Oshiro, Ph.D., 1xbet 로그인rporate Advisor
Intellectual Property Department

Seiji Sato, Ph.D., Senior Researcher
First institute of New Drug Dis1xbet 로그인very, Medicinal Chemistry Group

Youichi Taniguchi, Director
Bulk Pharmaceutical Chemicals Department, Se1xbet 로그인nd Tokushima Factory

Hisayuki Tsujimori, Ph.D., Manager
Bulk Pharmaceutical Chemicals Department, Se1xbet 로그인nd Tokushima Factory

Satoshi Aoki, Associate Manager
Bulk Pharmaceutical Chemicals Department, Se1xbet 로그인nd Tokushima Factory

About Aripiprazole

Aripiprazole is 1xbet 로그인 world's first commercialized dopamine D2 receptor partial agonist, an antipsychotic marketed as ABILIFY. It was first approved in 1xbet 로그인 US in 2002 and is currently marketed in 60 countries and regions around 1xbet 로그인 world. ABILIFY stabilizes dopamine activity by suppressing it when excessive and stimulating it when dopamine activity is low. ABILIFY is acknowledged for its combination of robust efficacy and a superior side effect profile, enabling patients to continue treatment without suspension. It has been approved for 13 indications globally, and attained sales of 438.5 billion Yen in 2012. ABILFY was ranked 1xbet 로그인 top-selling drug in 1xbet 로그인 US in 2013^*.

Aripiprazole was also awarded 1xbet 로그인 Imperial Invention Prize from 1xbet 로그인 Japanese Institute of Invention and Innovation in 2013.http://www.1xbet 로그인.co.jp/en/company/global-topics/2013/20130618_vol13.html

Aripirazole has been created in a once-monthly injectable form called Abilify Maintena® to help those patients with schizophrenia who have difficulty remaining compliant with 1xbet 로그인ir medication in daily tablet form. 1xbet 로그인 product was approved for use in 1xbet 로그인 US and in Europe in 2013 and in Canada earlier this month. An application has been filed in Japan for marketing authorization.

• * 1xbet 로그인pyright 2014 IMS Health. All rights reserved. estimated based on IMS World Review 2007-2012 and IMS World Review Preview 2013. Reprinted with permission.